Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol.
Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Reconstitución
Reconstitute in sterile water for a stock solution. Adjust the volume of sterile water so that, after reconstitution, the final stock concentration matches the value indicated on the product label or datasheet.
RECONSTITUTION PROTOCOL
1. Allow the product to be reconstituted and the reconstitution diluent to reach room temperature.
2. Tap or briefly centrifuge the product vial before opening to dislodge any lyophilized material that may be dispersed on the wall or cap of the vial.
3. Use the diluent and stock concentration recommended in the product datasheet. If preparing a stock concentration higher than recommended, contact Technical Service.
4. After adding the diluent, re-cap the vial and invert gently by hand or place on a slow rocking platform to allow the reconstitution diluent to coat all the surfaces inside the vial. Note: Do not mix by vortexing or by pipetting the material up and down.
5. Allow the vial to sit at room temperature with gentle agitation for at least 15 minutes before aliquotting or using.
6. Store the reconstituted material in single use aliquots in polypropylene or siliconized tubes. Aliquots of 10 μL or larger are recommended.
Envío
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Estabilidad y almacenamiento
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~32 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).
1. Tamura, H. et al. (2001) Blood 97, 1809-16. PMID: 11238124
2. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
3. Wang, S. et al. (2003) The Journal of experimental medicine 197, 1083-91. PMID: 12719480
Nota
For research use only.
Imágenes
SDS-PAGE
SDS-PAGE for Recombinant Mouse CD274/PD-L1/B7-H1 Protein, N-His
中文
English
한국어
日本語
Español
Français
Русский
